Merck & Co., Inc. $MRK Shares Sold by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co decreased its position in Merck & Co., Inc. (NYSE:MRK) by 54.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 33,000 shares of the company’s stock after selling 38,875 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Merck & Co., Inc. were worth $3,474,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Westside Investment Management Inc. grew its position in shares of Merck & Co., Inc. by 3.1% during the 4th quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after acquiring an additional 93 shares during the period. Valued Wealth Advisors LLC raised its holdings in Merck & Co., Inc. by 26.9% in the 4th quarter. Valued Wealth Advisors LLC now owns 444 shares of the company’s stock worth $47,000 after purchasing an additional 94 shares during the period. Payne Capital LLC raised its holdings in Merck & Co., Inc. by 0.9% in the 4th quarter. Payne Capital LLC now owns 10,637 shares of the company’s stock worth $1,120,000 after purchasing an additional 97 shares during the period. Abound Wealth Management boosted its position in Merck & Co., Inc. by 6.8% during the fourth quarter. Abound Wealth Management now owns 1,554 shares of the company’s stock worth $164,000 after purchasing an additional 99 shares in the last quarter. Finally, ST Germain D J Co. Inc. boosted its position in Merck & Co., Inc. by 0.3% during the fourth quarter. ST Germain D J Co. Inc. now owns 38,645 shares of the company’s stock worth $4,068,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction on Monday, February 9th. The shares were sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president owned 68,916 shares of the company’s stock, valued at $8,211,341.40. The trade was a 63.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total transaction of $1,184,100.00. Following the sale, the chief marketing officer directly owned 70,615 shares of the company’s stock, valued at $8,361,522.15. The trade was a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 320,176 shares of company stock valued at $38,281,735 in the last three months. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRK. Cantor Fitzgerald boosted their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. UBS Group increased their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Wolfe Research raised shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price target on the stock in a research note on Thursday, January 8th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Citigroup upped their price objective on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, March 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Trading Up 2.9%

MRK stock opened at $112.30 on Friday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The business’s 50-day moving average is $117.69 and its 200 day moving average is $107.54. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market cap of $277.36 billion, a price-to-earnings ratio of 31.63, a PEG ratio of 2.27 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 26.84% and a net margin of 13.59%.The business’s revenue was up 4.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 4.9 EPS for the current fiscal year.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.